APA (7th ed.) Citation

Prasad S. Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, . . . Bhagwat Gunale. (2024). Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Prasad S. Kulkarni, et al. Seropersistence of SII-ChAdOx1 NCoV-19 (COVID-19 Vaccine): 6-month Follow-up of a Randomized, Controlled, Observer-blind, Phase 2/3 Immuno-bridging Study in Indian Adults. Taylor & Francis Group, 2024.

MLA (9th ed.) Citation

Prasad S. Kulkarni, et al. Seropersistence of SII-ChAdOx1 NCoV-19 (COVID-19 Vaccine): 6-month Follow-up of a Randomized, Controlled, Observer-blind, Phase 2/3 Immuno-bridging Study in Indian Adults. Taylor & Francis Group, 2024.